Reasons behind the rise in demand for pDNA and what to look for in a pDNA engineering and manufacturing partner when deciding to outsource.

CDMOs bolster supply networks with additional capabilities to make themselves resilient to potential challenges and ensure secure supplies to customers.

CDMOs have moved to risk-based quality management systems comprising highly integrated and digitalized processes powered by data to ensure drug quality.

With the boom in pet ownership and rising awareness about pet health, veterinary drug makers are betting big on protein therapeutics and outsourcing biologics development to CDMOs.

Find out how offshoring has reached an inflection point as CROs turn risk-sharing partners in discovery research.

With sponsors having more oral solid dosage (OSD) products in their pipelines, CMOs anticipate an increasing trend in OSD outsourcing. Find out the criteria to choose the right CMO for OSD outsourcing.

Contract development manufacturing firms are ramping up the adoption of Pharma 4.0 technologies as regulators and customers increasingly seek transparency and integrity in manufacturing data.

Explore how Cell and Gene, mRNA, Bispecifics, and ADCs are turning the tide as CDMOs see service demand for these therapies soar.

Outsourcing of bioanalytical lab services is set for explosive growth as the increasingly complex nature of modern-day therapeutics makes partnerships with CROs indispensable.

A number of CDMOs are accelerating their environmental drive as sustainability goals become one of the most urgent business strategies facing pharma companies today.